Skip to content
OpenCapital
Get started

Stoke Therapeutics, Inc. STOK Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$10.6MBeat by $6.1MDiluted EPS-$0.65Miss by $0.11
Revenue estimate$4.6M
EPS estimate-$0.54

Next report

Aug 11, 2026 (in a month)
Revenue estimate$5.4M
EPS estimate-$0.82

Financials

Q3 2025

Income statement

See full
Revenue$10.6M+117%
Operating income-$43.1M-43.6%
Net income-$38.3M-45.1%
EPS (diluted)-$0.65-38.3%

Balance sheet

See full
Cash & equivalents$83.4M-44.4%
Total debt$1.8M-66.1%
Total equity$308.1M+32.7%
Total assets$360.3M+22.8%

Cash flow

See full
CapEx$132.0K+28.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.29B+87.9%
Enterprise value$1.21B+123%
P/E31.7×—
P/S6.3×-34.7×

Profitability

See full
Operating margin13.2%+6.7pp
Net margin19.7%+10.0pp

Returns & leverage

See full
Return on equity15%+8.5pp
Debt / equity0×0.0×
Current ratio6.5×+1.4×

Versus estimates

Revenue

Q1 2026$6.2MMiss by $254.3KQ4 2025$1.4MMiss by $4.4M
Q3 2025$10.6MBeat by $6.1M
Q2 2025$13.8MBeat by $8.5MQ1 2025$158.6MBeat by $127.1MQ4 2024$22.6MBeat by $18.8M

Diluted EPS

Q1 2026-$0.79Beat by $0.01Q4 2025-$0.97Miss by $0.22
Q3 2025-$0.65Miss by $0.11
Q2 2025-$0.40Beat by $0.17Q1 2025$1.90Beat by $2.27Q4 2024-$0.18Beat by $0.33

Ask the moment Stoke Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Stoke Therapeutics, Inc. report Q3 2025 earnings?
Stoke Therapeutics, Inc. (STOK) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Stoke Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Stoke Therapeutics, Inc. reported revenue of $10.6M and diluted EPS of $-0.65 for Q3 2025.
Did Stoke Therapeutics, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $4.6M by $6.1M. EPS missed the consensus estimate of $-0.54 by $0.11.
How did Stoke Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 117.2% from $4.9M a year earlier and diluted EPS declined 38.3% from $-0.47.
Where can I find Stoke Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-264644) and the 10-Q periodic report (0001193125-25-264720) directly on SEC EDGAR. The filing index links above go to sec.gov.